{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333E
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M020
(2020)
Source URL:
First approved in 2020
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Stepronin is clinically used as an expectorant. It inhibits airway secretion in vitro by both decreasing Cl- secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands. The mucolytic activity of stepronine does not involve the gastric mucous coating and that the drug does not exert adverse effects on the gastric mucosa. It is a new chemical immunosuppressant drug, which has the effect of preventing graft-versus-host-disease (GVHD) in a mouse model. The mechanism by which this compound acts as an immunosuppressant appears to be similar to cyclosporine A (CyA), although, in contrast to CyA, it is not toxic for animals and humans. Stepronin has an antiviral effect as well and is able to block, indirectly, the human immunodeficiency virus–1 (HIV-1) replication in mononuclear cells in vitro.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333E
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Butidrine is naphthalenemethanol devivative with β-adrenolytic, antiarrhythmic, and local anesthetic properties having sympatholytic and antiarrhythmic effects comparable to those of pronethalol and propranolol.
Status:
Possibly Marketed Outside US
Source:
Disinfectant by Shenzhen Haiyin Hongye Technology Co., Ltd.
(2020)
Source URL:
First approved in 2020
Source:
Disinfectant by Shenzhen Haiyin Hongye Technology Co., Ltd.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Impacarzine is cyclic urea derivative patented by pharmaceutical company Asta-Werke A.-G. as antiviral agent. In preclinical models Impacarzine gave 25% protection to mice infected with Influenza A2/Hongkong virus.
